Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

Phase 3Not Yet RecruitingNCT07013279

Daewoong Pharmaceutical Co. LTD.324 enrolled

Overview

To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

324

Conditions

Glabellar Lines

Interventions

DWP712 inj.BIOLOGICAL

Clostridium botulinum Toxin

Botox® 100 UnitsBIOLOGICAL

Clostridium botulinum Toxin

Eligibility

Sex: ALLMin age: 19 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: \- Subjects with a facial wrinkle scale (FWS) score of ≥2 (moderate) for glabellar lines at maximum frown in the investigator's on-site assessment at screening Exclusion Criteria: \- Subjects with glabellar lines that cannot sufficiently be improved by physical attempts, e.g., glabellar lines not flattened by hand, in the judgment of the investigator

Locations (1)

Chung-Ang University Hosptial

Seoul, South Korea

Outcomes

Primary Outcomes

Percentage of subjects with glabellar line improvement* rate at maximum frown based on the investigator's on-site assessment at 4 weeks after IP administration

Improvement means FWS grade of "0" or "1" with a ≥2-point improvement from baseline

Time frame: At 4 weeks after IP administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.